Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis

OBJECTIVE. Olaparib treatment resulted in significant improvement in objective response rates (ORRs) and progression-free survival (PFS) over non-platinum chemotherapy in patients with BRCA1/BRCA2-mutated (BRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) and ≥2 prior lines of platinum-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadoo, Karen, Simpkins, Fiona, Mathews, Cara, Liu, Ying L., Provencher, Diane, McCormick, Colleen, ElNaggar, Adam C., Altman, Alon D., Gilbert, Lucy, Black, Destin, Kabil, Nashwa, Bennett, James, Munley, Jiefen, Aghajanian, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909678/
https://www.ncbi.nlm.nih.gov/pubmed/35803835
http://dx.doi.org/10.1016/j.ygyno.2022.06.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909678/
https://www.ncbi.nlm.nih.gov/pubmed/35803835
http://dx.doi.org/10.1016/j.ygyno.2022.06.017

Ejemplares similares